Publications by authors named "Michael A Pacanowski"

Claim this Profile
L
Landscape of FDA-Approved Targeted Therapies for the Treatment of Diseases with Low Frequency Molecular Subsets.
Lois S Akinola, Sarah Ridge, Issam Zineh, Michael A Pacanowski, Anuradha Ramamoorthy

J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute pain pathways: protocol for a prospective cohort study.
Molly Moore Jeffery, Mitra Ahadpour, Summer Allen, Richardae Araojo, Fernanda Bellolio, Michael A Pacanowski

BMJ Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
Rajanikanth Madabushi, Jessica M Benjamin, Renmeet Grewal, Michael A Pacanowski, David G Strauss

Clin Pharmacol Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective.
Katarzyna Drozda, Michael A Pacanowski, Christian Grimstein, Issam Zineh

JACC Basic Transl Sci· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic Testing.
Katarzyna Drozda, Michael A Pacanowski

Pharmacotherapy· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
Kelly K Filipski, Michael A Pacanowski, Anuradha Ramamoorthy, William Gregory Feero, Andrew N Freedman

Pharmacogenet Genomics· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases.
Robert L Davis, Mia A Gallagher, Maryam M Asgari, Melody J Eide, David J Margolis, Michael A Pacanowski

Pharmacoepidemiol Drug Saf· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
Richard B Horenstein, Rajnikanth Madabushi, Issam Zineh, Laura M Yerges-Armstrong, Cody J Peer, Michael A Pacanowski

J Clin Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Jason H Karnes, Yan Gong, Michael A Pacanowski, Caitrin W McDonough, Meghan J Arwood

Pharmacogenet Genomics· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New evidence about an old drug--risk with codeine after adenotonsillectomy.
Judith A Racoosin, David W Roberson, Michael A Pacanowski, David R Nielsen

N Engl J Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
Joshua P Lewis, Richard B Horenstein, Kathleen Ryan, Jeffrey R O'Connell, Quince Gibson, Michael A Pacanowski

Pharmacogenet Genomics· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels.
Daniela J Conrado, Hobart L Rogers, Issam Zineh, Michael A Pacanowski

Pharmacogenomics· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma.
Cody J Peer, Shawn D Spencer, Dustin A H VanDenBerg, Michael A Pacanowski, Richard B Horenstein

J Chromatogr B Analyt Technol Biomed Life Sci· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allopurinol pharmacogenetics: assessment of potential clinical usefulness.
Issam Zineh, Padmaja Mummaneni, Jenna Lyndly, Shashi Amur, Lois A La Grenade, Michael A Pacanowski

Pharmacogenomics· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Jaekyu Shin, Daniel F Pauly, Michael A Pacanowski, Taimour Langaee, Reginald F Frye

Pharmacotherapy· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
Issam Zineh, Michael A Pacanowski

Pharmacotherapy· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Elvin Tyrone Price, Michael A Pacanowski, Michael A Martin, Rhonda M Cooper-DeHoff, Carl J Pepine

Pharmacogenet Genomics· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
Linda C Surh, Michael A Pacanowski, Susanne B Haga, Stuart Hobbs, Lawrence J Lesko

Pharmacogenomics· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and regulatory strategies for drug and diagnostic co-development.
Lois M Hinman, Kevin M Carl, Brian B Spear, Ronald A Salerno, Robert L Becker, Michael A Pacanowski

Pharmacogenomics· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine.
Kim E Sapsford, Zivana Tezak, Marina Kondratovich, Michael A Pacanowski, Issam Zineh

Ther Deliv· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.
Greg Welder, Issam Zineh, Michael A Pacanowski, Jason S Troutt, Guoqing Cao

J Lipid Res· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
Michael A Pacanowski, Issam Zineh, Rhonda M Cooper-Dehoff, Carl J Pepine, Julie A Johnson

Am J Hypertens· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.
Rhonda M Cooper-DeHoff, Michael A Pacanowski, Carl J Pepine

J Am Coll Cardiol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose Atorvastatin.
Michael A Pacanowski, Reginald F Frye, Osatohanmen Enogieru, Richard S Schofield, Issam Zineh

J Clin Lipidol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms.
Michael A Pacanowski, Charles W Hopley, Christina L Aquilante

Expert Opin Drug Metab Toxicol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis